Loading…
Back To Schedule
Wednesday, June 21 • 4:00pm - 5:15pm
#368: FDA Update on Prescription Drug Promotion

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Forum
Level: Intermediate
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-519-L04-P; CME 1.25; IACET 1.25; RN 1.25

FDA marketing officials from the CDER Office of Prescription Drug Promotion and other related centers will outline the latest major enforcement actions and regulatory guidance and explain major priorities in enforcement actions and area of enforcement concern. Participants can expect a review of the structure and priorities of the marketing enforcement centers, including review of warning letters and current guidances.

Invitations to FDA Marketing Executives are currently pending.

Learning Objectives

Describe the latest enforcement priorities and warning letters from FDA OPDP and other enforcement centers that focus on marketing matters.

Chair

John Kamp

Speaker

OPDP Enforcement and Guidance Updates
Thomas W. Abrams, MBA

Social Science Research
Helen W. Sullivan, PhD, MPH


Moderators
avatar for John Kamp

John Kamp

Executive Director, Coalition For Healthcare Communication
Dr. John F. Kamp is Executive Director of the Coalition for Healthcare Communication, a medical marketing trade association with offices in New York City and Washington, DC. He is also Consulting Counsel with the law firm Wiley Rein LLP, and is a widely respected advocate for First... Read More →

Speakers
avatar for Thomas Abrams

Thomas Abrams

Director, Office of Prescription Drug Promotion, OMP, CDER, FDA
Thomas Abrams is the Director of the Office of Prescription Drug Promotion (formerly the Division of Drug Marketing, Advertising, and Communications (DDMAC)), Food and Drug Administration. He joined FDA as a reviewer in DDMAC. Prior to joining FDA, Mr. Abrams worked in pharmaceutical... Read More →
HS

Helen Sullivan

Social Science Analyst, OPDP, CDER, FDA
Helen Sullivan, PhD, MPH is a Social Science Analyst in the Office of Prescription Drug Promotion at the U.S. Food and Drug Administration (FDA). Prior to joining FDA, she was a Cancer Prevention Fellow at the National Cancer Institute. She received her BA from Yale University; her... Read More →

Wednesday June 21, 2017 4:00pm - 5:15pm CDT
N227b McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  03: MedAffairs-SciComm, Forum